Cargando…

Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and mortality. Even though progress have been accomplished in the management of type 2 diabetes, current treatment preferences for patients with this disease still fall short to address disease progression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dharmalingam, Mala, Sriram, Usha, Baruah, Manash P.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079863/ https://www.ncbi.nlm.nih.gov/pubmed/21584160 http://dx.doi.org/10.4103/2230-8210.77571

Ejemplares similares

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
por: van Can, J, et al.
Publicado: (2014)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
por: Wang, Bruce, et al.
Publicado: (2015)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
por: Baruah, Manash P., et al.
Publicado: (2016)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Importance of achieving the composite endpoints in diabetes
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2013)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders, William B, et al.
Publicado: (2016)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study
por: Ishii, Hitoshi, et al.
Publicado: (2017)

GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy
por: Shiraki, Aya, et al.
Publicado: (2019)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
por: Buse, John B., et al.
Publicado: (2010)

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
por: Barnett, A H
Publicado: (2012)

Health economics in India: The case of diabetes mellitus
por: Sahay, Rakesh, et al.
Publicado: (2014)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Renaming gestational diabetes mellitus: A psychosocial argument
por: Kalra, Bharti, et al.
Publicado: (2013)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2018)

Management of diabetes mellitus type-2 in the geriatric population: Current perspectives
por: Bajwa, Sukhminder Jit Singh, et al.
Publicado: (2014)

The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction
por: Diz-Chaves, Y., et al.
Publicado: (2018)

Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
por: Ismail, Ruba, et al.
Publicado: (2019)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
por: Baruah, Manash P., et al.
Publicado: (2016)

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
por: Courrèges, J-P, et al.
Publicado: (2008)

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
por: Kalra, Sanjay, et al.
Publicado: (2019)

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
por: Marre, M, et al.
Publicado: (2009)

Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
por: Kapitza, Christoph, et al.
Publicado: (2015)

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
por: Krasner, Nadia M., et al.
Publicado: (2014)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_269nic9co5abokpbusmt4d60ql